<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195828</url>
  </required_header>
  <id_info>
    <org_study_id>Arise-FJ-G005</org_study_id>
    <nct_id>NCT04195828</nct_id>
  </id_info>
  <brief_title>Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer</brief_title>
  <official_title>Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate,
      nab-paclitaxel and S-1
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathologic complete response</measure>
    <time_frame>4 months</time_frame>
    <description>pathologic complete response（pCR）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>4 months</time_frame>
    <description>Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>4 months</time_frame>
    <description>The surgical procedure was total or subtotal gastrectomy with 3 weeks after total neoadjuvant therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel +S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab combined with Apatinib mesylate tablets, nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nab-paclitaxel +S-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nab-paclitaxel and S-1 in the treatment of locally advanced gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel +S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel +S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel +S-1</arm_group_label>
    <arm_group_label>nab-paclitaxel +S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S1</intervention_name>
    <description>S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:&lt;1.25m2, 40mg every time;1.25-1.5m2,50mg every time; &gt;1.5m2, 60mg every time</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel +S-1</arm_group_label>
    <arm_group_label>nab-paclitaxel +S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-70 years of age

          -  Gastric adenocarcinoma was confirmed by pathology（ including histology or cytology）。

          -  CT/MRI,PET-CT or laparoscopic exploration were used to confirm the diagnosis of
             gastric cancer staging as cT2-4a and/or N+ and M0 before operation.

          -  measurable lesions at least should be detected by CT/MRI examination in accordance
             with the RECIST1.1.（CT scan of tumor lesion length≥10mm，CT scan short
             diameter≥15mm，scan slice thicknes 5mm）

          -  ECOG（Eastern Cooperative Oncology Group）PS（Performance Status）:0-1 scores;

          -  the expected survival time is more than 12 weeks

          -  the main organ function is normal, which should meet the following criteria:

             (1) blood routine examination standards should be met（no blood transfusion within 14
             days）

             a．HB≥ 100g/L b. WBC≥3×109/L c. ANC≥1.5×109/L d. PLT≥100×109/L （2）biochemical
             examination shall comply with the following criteria：

               1. BIL＜1.5 normal upper limit ULN

               2. ALT and AST＜2.5 ULN,GPT≤1.5×ULN

               3. Cr≤1 ULN，CCR（creatinine clearance rate）＞60ml/min(Cockcroft-Gault formula)

          -  women of childbearing age must have a pregnancy test in 7 days before entering the
             group (in serum), and the results were negative, and willing to use appropriate
             contraception during the study period and the last 8 weeks after giving drug test; men
             should have the surgical sterilization, or adopt the appropriate contraceptive methods
             during the test and the last 8 weeks after giving drug test。

          -  No other clinical studies were conducted before and during the treatment

          -  participants is willing to participate in this study, sign the informed consent, have
             good compliance, cooperate with follow-up.

        Exclusion Criteria:

          -  Previous history of chemotherapy, radiotherapy, targeted drug therapy or immunotherapy

          -  Patients with contraindications for surgical treatment and chemotherapy or whose
             physical condition and organ function do not allow for larger abdominal surgery

          -  patients with metastasis

          -  Having any active autoimmune diseases or a history of autoimmune diseases (such as
             interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation,
             vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, including but not
             limited to these diseases or syndromes); Patients with vitiligo or cured childhood
             asthma/allergies who did not need any intervention in adulthood were excluded;
             Autoimmune hypothyroidism treated with a stable dose of thyroid replacement hormone;
             Type 1 diabetes with stable doses of insulin

          -  A history of immunodeficiency, including HIV testing positive, or other acquired or
             congenital immunodeficiency disorders, or a history of organ transplantation and
             allogeneic bone marrow transplantation

          -  Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease;
             Jaundice or obstruction of the digestive tract with severe infection

          -  pregnant or lactating women

          -  The blood pressure of patients with hypertension cannot be reduced to the normal range
             by the antihypertensive drugs (systolic pressure &gt;140 mmHg, diastolic pressure &gt;90
             mmHg)

          -  With Ⅰ magnitude of coronary heart disease, arrhythmia (including QTc protracted
             between male &gt; 450 ms, women &gt; 470 ms) and cardiac insufficiency

          -  Patients have a clear tendency with gastrointestinal bleeding, including the following
             situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena
             and hematemesis history in 2 months; and patients with fecal occult blood (+) and
             unresected gastric primary tumor; patients with the risk of bleeding should take the
             gastroscopy test, if it is the gastric cancer, and researchers believe that may
             results in massive digestive tract hemorrhage；coagulation dysfunction
             (INR(international normalized ratio)&gt;1.5, APTT(activated partial thromboplastin
             time)&gt;1.5 ULN), with bleeding tendency;

          -  Subjects have failed to control good cardiovascular clinical symptoms or disease,
             including but not limited to: such as: (1) the NYHA class II heart failure (2) above
             unstable angina pectoris (3) occurred within 1 year (4) have clinical significance of
             myocardial infarction (mi) room sex or ventricular arrhythmias without clinical
             intervention on or after clinical intervention is still poorly controlled

          -  History of interstitial lung disease (except radiation pneumonia without hormone
             therapy), and history of non-infectious pneumonia

          -  Patients are positive of urine protein (urine protein detection 2+ or above, or 24
             hours urine protein quantitative &gt;1.0g);

          -  A person who has previously been allergic to any component of camrilizumab or to any
             component of the drug under study

          -  The researchers consider those who were not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changming Huang, Professor</last_name>
      <phone>8613805069676</phone>
      <email>hcmlr2002@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University Union Hospital</investigator_affiliation>
    <investigator_full_name>Chang-Ming Huang, Prof.</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

